Davis's Drug Guide
mavacamten
General
**REMS Drug**
Genetic Implications:
Pronunciation:
mav-a-kam-ten
Trade Name(s)
- Camzyos
Ther. Class.
heart failure agents
Pharm. Class.
temporary class
cardiac myosin inhibitorThere's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Mavacamten." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580063/6/mavacamten.
Vallerand AHA, Sanoski CAC. Mavacamten. Davis's Drug Guide. F.A. Davis Company; 2026. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580063/6/mavacamten. Accessed June 25, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Mavacamten. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580063/6/mavacamten
Vallerand AHA, Sanoski CAC. Mavacamten [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 June 25]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580063/6/mavacamten.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - mavacamten
ID - 3580063
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580063/6/mavacamten
PB - F.A. Davis Company
ET - 20
DB - Pediatrics Central
DP - Unbound Medicine
ER -
